Conclusions: The increases in diversion and abuse measures indicate the need to take active attempts to curb diversion and abuse as well as continuous monitoring and surveillance of all buprenorphine products. However, these increases parallel the increased number of tablets sold. Finding a balance of risk/benefit (i.e. diversion and abuse versus expanded treatment) remains a challenge. (Source: Drug and Alcohol Dependence)
Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians
Previous post: Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care
Next post: Compensation Effects on Clinical Trial Data Collection in Opioid-Dependent Young Adults.
